Key result
Anticoagulation-free pediatric ECMO resulted in thrombotic events in 8% (3/35) of patients, associated with younger age, lower weight, and longer duration.
Why the study?
This study aimed to analyze hemorrhage and thrombosis data related to anticoagulation-free pediatric extracorporeal membrane oxygenation (ECMO).
What is the frequency and risk profile of hemorrhage and thrombosis during anticoagulation-free periods in pediatric patients supported with ECMO?
Cohort (n=35)
No
What is the frequency and risk profile of hemorrhage and thrombosis during anticoagulation-free periods in pediatric patients supported with ECMO?
Answers are grounded in this paper and cite their sources.
In selected high-risk-for-bleeding pediatric patients, ECMO can be used for limited periods without systemic anticoagulation with an 8% patient incidence of thrombotic events during the anticoagulation-free period, though younger, smaller patients with lower flow rates and longer anticoagulation-free durations face higher clotting risk.
Objectives: To analyze hemorrhage and thrombosis data related to anticoagulation-free pediatric extracorporeal membrane oxygenation (ECMO). Design: Retrospective cohort study. Settings: High-volume ECMO single institution data. Patients: Children (0–18 yr) supported with ECMO (>24 hr) with initial anticoagulation-free period of greater than or equal to 6 hours. Interventions: None. Measurements and Main Results: Utilizing consensus American Thoracic Society definitions for hemorrhage and thrombosis on ECMO, we evaluated thrombosis and associated patient and ECMO characteristics during anticoagulation-free period. Thirty-five patients met inclusion criteria from 2018 to 2021 having a median age (interquartile range [IQR]) of 13.5 months (IQR, 3–91 mo), median ECMO duration of 135 hours (IQR, 64–217 hr), and 964 anticoagulation-free hours. Increased RBC transfusion needs were associated with longer anticoagulation-free periods (p = 0.03). We identified 20 thrombotic events: only four during the anticoagulation-free period and occurring in three of 35 (8%) patients. Compared with those without thrombotic events, anticoagulation-free clotting events were associated with younger age (i.e., 0.3 mo [IQR, 0.2–0.3 mo] vs 22.9 mo [IQR, 3.6–112.9 mo]; p = 0.02), lower weight (2.7 kg [IQR, 2.7–3.25 kg] vs 13.2 kg [5.9–36.4 kg]; p = 0.006), support with lower median ECMO flow rate (0.5 kg [IQR, 0.45–0.55 kg] vs 1.25 kg [IQR, 0.65–2.5 kg]; p = 0.04), and longer anticoagulation-free ECMO duration (44.5 hr [IQR, 40–85 hr] vs 17.6 hr [IQR, 13–24.1]; p = 0.008). Conclusions: In selected high-risk-for-bleeding patients, our experience is that we can use ECMO in our center for limited periods without systemic anticoagulation, with lower frequency of patient or circuit thrombosis. Larger multicentered studies are required to assess weight, age, ECMO flow, and anticoagulation-free time limitations that are likely to pose risk for thrombotic events.
No takes yet. Share an insight, caveat, or question.
Rabinowitz et al. (2023) conducted a cohort in Pediatric extracorporeal membrane oxygenation (ECMO) support (n=35). Anticoagulation-free pediatric ECMO was evaluated on Thrombotic events during the anticoagulation-free period. Anticoagulation-free pediatric ECMO resulted in thrombotic events in 8% (3/35) of patients, associated with younger age, lower weight, and longer duration.
Synapse has enriched 10 related papers. Consider them for comparative context: